TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1751666
Drug: Parenteral administration
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral administration of hemostimulants, hemosubstitutes and detoxicants (group II)
Study: 6818596
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) 12.5 mg
Study: 6818596
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) 25.0 mg
Study: 15813835
Drug: Capsules taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules taken just before meals (schedule A)
Study: 15813835
Drug: Capsules taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules taken just after meals (schedule B)
Study: 15813835
Drug: Capsules taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules taken along with meals (schedule C)
Study: 12748463
Drug: EE/levonorgestrel (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/levonorgestrel (0.3 mg ethinyl estradiol / 0.15 mg levonorgestrel)
Study: 12748463
Drug: EE/desogestrel (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/desogestrel (0.3 mg ethinyl estradiol / 0.15 mg desogestrel)
Study: 8792107
Drug: Pooled Micral-Test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled Micral-Test result (> or = 15 mg/l)
Study: 1352370
Drug: RU 42
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 42 173 (0.25 mg single oral dose)
Study: 6397914
Drug: Herbal combination
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal combination Dietosan (species)
Study: 6397914
Drug: Herbal combination
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal combination Dietosan (disperg)
Study: 6397914
Drug: Herbal combination
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal combination Dietosan (species) with glybenclamide
Study: 6397914
Drug: Herbal combination
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal combination Dietosan (disperg) with glybenclamide
Study: 6397914
Drug: Herbal combination
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal combination Dietosan (species and disperg)
Study: 30964820
Drug: Oropharyngeal colostrum
Normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal colostrum administration (0.2 mL every 2 hours for 48 hours)
Study: 30964820
Drug: Placebo (sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sterile water, 0.2 mL every 2 hours for 48 hours)
Study: 30964820
Drug: Oropharyngeal colostrum
Normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal colostrum administration
Study: 27223302
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (65 g)
Study: 27223302
Drug: Yerba mate
Normalized name: yerba mate
DrugBank: Ilex paraguariensis leaf (DB14366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yerba mate (3 g)
Study: 22424011
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of loop diuretics and spironolactone use
Study: 22424011
Drug: Angiotensin‐converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin‐converting enzyme inhibitor, angiotensin receptor blocker, and β‐blocker use
Study: 31116848
Drug: Conservative Medical
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative Medical Therapy (CMT)
Study: 10989854
Drug: 4 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 microg/kg remifentanil and 3.5 mg/kg propofol
Study: 9192229
Drug: Education through
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education through monthly newsletters and semiannual classes on nutrition and exercise
Study: 1311666
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium metered dose aerosol 4 mg twice daily
Study: 3923726
Drug: prazosin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: prazosin 20 mg/d orally (n = 12)
Study: 30572270
Drug: Pea fiber
Normalized name: Pea fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pea fiber (PF, 15 g/d in wafer form; n=29)
Study: 16632811
Drug: Acetaminophen 60
Normalized name: acetaminophen 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 60 mg/kg rectally and 40 mg/kg orally
Study: 16632811
Drug: Ketoprofen 2
Normalized name: ketoprofen 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 2 mg/kg IV twice
Study: 16632811
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetaminophen and ketoprofen
Study: 10780130
Drug: Universal preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal preventive intervention for conduct disorder; specific dosage and duration not mentioned.
Study: 8737186
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (0.01 microgram/kg/min)
Study: 8737186
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg as i.v. bolus)
Study: 8737186
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion followed by metoclopramide (10 mg bolus after 2 hours)
Study: 8737186
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (4-hour)
Study: 29604894
Drug: Global ground-state
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Global ground-state potential energy surface (PES) for triplet O4 based on MS-CASPT2/maug-cc-pVTZ electronic structure calculations.
Study: 19508580
Drug: Zinc oxide
Normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc oxide cream
Study: 24399554
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (varenicline and bupropion SR)
Study: 24399554
Drug: Varenicline monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline monotherapy
Study: 18343249
Drug: CH-1504 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CH-1504 (1, 5, 7.5, 10, 15, or 20 mg)
Study: 18343249
Drug: CH-1504 (7.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CH-1504 (7.5, 10, or 15 mg)
Study: 16005507
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - fresh dentin with no surface treatment
Study: 9030363
Drug: Control treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatments (other treatment arms)
Study: 7967434
Drug: Erwinia L-asparaginase
Normalized name: Erwinia L-asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erwinia L-asparaginase therapy
Study: 7967434
Drug: Prophylactic use
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic use of anticoagulants (under investigation)
Study: 11952670
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid applied twice daily starting from day 4
Study: 11952670
Drug: Vehicle applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle applied twice daily starting from day 4
Study: 29660190
Drug: HBVaxPro©‐10 μg vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBVaxPro©‐10 μg vaccine
Study: 27002062
Drug: Brivaracetam (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam (150 mg single oral dose)
Study: 27002062
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg/day for 5 days)
Study: 24297971
Drug: Social networks
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social networks intervention (peer support, monthly diabetes education sessions)
Study: 20167142
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP), 88 micrograms, twice daily
Study: 20167142
Drug: Montelukast, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast, 10 mg, daily
Study: 18560254
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural treatment and cognitive strategy training (8 group sessions each)
Study: 12463081
Drug: Insoluble iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insoluble iodine skin preparation
Study: 12463081
Drug: Other skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other skin preparation methods
Study: 7025883
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) vaginal pessaries (10 mg)
Study: 7025883
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) vaginal pessaries (5 mg)
Study: 28764579
Drug: Intravaginal dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravaginal dinoprostone tablet placement
Study: 22024956
Drug: Creative arts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creative arts as a complementary therapy
Study: 2865859
Drug: famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 40 mg nocte
Study: 2891224
Drug: famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 20 mg bid
Study: 2891224
Drug: famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 40 mg bid
Study: 28675812
Drug: Dexamethasone, 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone, 8 mg
Study: 28675812
Drug: Diclofenac sodium,
Normalized name: diclofenac sodium, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac sodium, 50 mg associated with codeine, 50 mg
Study: 27447477
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac (50 mg) before and after ERCP
Study: 27447477
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac (50 mg) in high-risk patients
Study: 27447477
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac (50 mg) in low-risk patients
Study: 27447477
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac (50 mg)
Study: 20923960
Drug: Low intravenous
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intravenous fat (32 g)
Study: 20923960
Drug: High intravenous
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intravenous fat (64 g)
Study: 20923960
Drug: Low oral
Normalized name: Milkflow oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low oral fat (32 g)
Study: 20923960
Drug: High oral
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oral fat (64 g)
Study: 12428181
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (CoQ) supplementation (100 mg twice daily for 12 weeks)
Study: 12428181
Drug: Fenofibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (200 mg each morning for 12 weeks)
Study: 22498212
Drug: Radiation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation plus androgen deprivation therapy
Study: 11803183
Drug: Clopidogrel (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (initial 300-mg loading dose, followed by 75-mg daily dose)
Study: 2199290
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg orally every morning)
Study: 400861
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg NA‐872 daily for 5 days
Study: 400861
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg NA‐872 daily for 5 days
Study: 7119300
Drug: Prednisone tablet
Normalized name: Prednisone Tablets
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone tablet
Study: 25137188
Drug: Fluoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine treatment over 12 weeks (8 sessions)
Study: 15230343
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg disodium clodronate with 1% lidocaine
Study: 15230343
Drug: Clody (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clody (same formulation without local anaesthetic)
Study: 15230343
Drug: Clasteon (marketed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clasteon (marketed formulation containing 1% benzyl alcohol)
Study: 7911813
Drug: Cabergoline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.5 mg twice weekly)
Study: 7911813
Drug: Quinagolide (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinagolide (75 micrograms once daily)
Study: 26688732
Drug: Ciprofloxacin DPI
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin DPI 48.75 mg
Study: 26688732
Drug: Placebo 32.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 32.5 mg
Study: 26688732
Drug: Placebo 48.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 48.75 mg
Study: 23576486
Drug: Cetuximab in
Normalized name: cetuximab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil
Study: 21041278
Drug: Atorvastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin therapy (40 mg/day) combined with methotrexate (MTX; 0.2 mg/kg/week) and prednisone (10 mg/day)
Study: 21041278
Drug: Methotrexate (MTX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (MTX; 0.2 mg/kg/week) plus prednisone (10 mg/day)
Study: 17219217
Drug: Alprazolam XR
Normalized name: ALPRAZOLAM 2 mg ORAL TABLET, EXTENDED RELEASE [Alprazolam XR]
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam XR (1 mg)
Study: 17219217
Drug: Alprazolam IR
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam IR (1 mg)
Study: 11059965
Drug: Salmeterol added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol added to low-dose inhaled corticosteroids (ICS)
Study: 8872688
Drug: Midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.5 mg/kg orally
Study: 1623899
Drug: Metamizole 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizole 3 x 1 g for 3 days
Study: 1623899
Drug: Furosemide 20
Normalized name: furosemide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 20 mg IV
Study: 20409311
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aerobic and resistance training
Study: 15710957
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with pegylated interferon-alpha2b (1.5 microg/kg/week for 32 weeks) plus lamivudine (100 mg daily for 52 weeks)
Study: 15710957
Drug: Lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine monotherapy (100 mg daily for 52 weeks)
Study: 12804927
Drug: High CRP
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High CRP group (CRP >12 mg/l)
Study: 12804927
Drug: Low CRP
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low CRP group (CRP ≤12 mg/l)
Study: 11029125
Drug: Tramadol drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol drops (2.5 mg kg(‐1))
Study: 11029125
Drug: Paracetamol (acetaminophen)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (acetaminophen) suppositories (15 mg kg(‐1))
Study: 8711649
Drug: Inhaled bronchodilators
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bronchodilators or steroids
Study: 8711649
Drug: Potential improvement
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential improvement on treatment
Study: 1355345
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg/day for 15 days
Study: 1355345
Drug: Astemizole 10
Normalized name: astemizole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole 10 mg/day for 15 days
Study: 6432869
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (NG) for 48 hours
Study: 31731467
Drug: Coffee ingestion
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee ingestion (0.09 g·kg‐1 coffee providing 3 mg·kg‐1 of caffeine)
Study: 25583754
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg/linagliptin 5 mg
Study: 25583754
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg/linagliptin 5 mg
Study: 18758125
Drug: Rosuvastatin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 2.5 mg/dL
Study: 18758125
Drug: Non-rosuvastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-rosuvastatin therapy
Study: 12621384
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg orally twice a day for 2 days
Study: 12621384
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice 200 mL 3 times a day for 2 days
Study: 10321418
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg conventional ondansetron tablet (OT) taken twice daily
Study: 10321418
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg orally disintegrating ondansetron tablet (ODT) taken twice daily
Study: 2883698
Drug: midazolam 15
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 15 mg orally followed by intravenous saline
Study: 2883698
Drug: oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo followed by intravenous diazepam 10 mg (Diazemuls)
Study: 25186034
Drug: Placebo advanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo advanced to tofacitinib 5 mg twice daily
Study: 25186034
Drug: Placebo advanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo advanced to tofacitinib 10 mg twice daily
Study: 23850450
Drug: AC-T without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AC-T without primary G-CSF prophylaxis
Study: 23850450
Drug: TAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC with primary G-CSF prophylaxis
Study: 21670542
Drug: Apixaban 2.5
Normalized name: apixaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 2.5 mg b.i.d.
Study: 21670542
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg b.i.d.
Study: 21670542
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target INR 2.0-3.0; 2.0-2.6 if age ≥ 70 years)
Study: 19567532
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg DHEA daily for 2 years (women)
Study: 19567532
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg DHEA daily for 2 years (men)
Study: 19567532
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg testosterone (patch) daily for 2 years (men)
Study: 19567532
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 2 years (women and men)
Study: 16123739
Drug: DMT (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT (low dose)
Study: 16123739
Drug: DMT (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT (high dose)
Study: 16123739
Drug: S-ketamine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (low dose)
Study: 16123739
Drug: S-ketamine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (high dose)
Study: 11313302
Drug: CDP571 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP571 (10 or 20 mg/kg)
Study: 7977475
Drug: Cefuroxime axetil,
Normalized name: Cefuroxime Axetil, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime axetil, 125 mg twice a day for 2 days
Study: 7977475
Drug: Cefuroxime axetil,
Normalized name: Cefuroxime Axetil, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime axetil, 125 mg twice a day for 10 days
Study: 23341981
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow mononuclear cell transplantation (BMMCT) combined with standard medical therapy (SMT)
Study: 20462466
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus Self-Administered Cognitive Behavior Therapy (SCBT)
Study: 9372546
Drug: Porfiromycin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porfiromycin (50 mg/M2, 45 mg/M2, 40 mg/M2) with radiation therapy (RT)
Study: 9372546
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C with radiation therapy (RT)
Study: 8403155
Drug: Intrathecal meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal meperidine 1 mg.kg‐1
Study: 8403155
Drug: 5% heavy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% heavy lidocaine 1.2 to 1.4 ml intrathecally